质子治疗颅内脑膜瘤:单中心回顾性分析疗效、生存与毒性结局
该单中心回顾性分析纳入2014至2021年连续接受根治性质子治疗的167例颅内脑膜瘤患者,中位随访41个月,5年局部无复发生存率全队列为88%,良性/影像诊断组98% vs 非典型/间变性组47%(p<0.001),3级急性与晚期毒性分别2例(1.2%)与3例(1.8%),无4-5级不良事件。
要点
- 5年局部无复发生存率全队列88%,良性/影像诊断组98% vs 非典型/间变性组47%(p<0.001)。
- 5年总生存与5年远处无复发生存率在两组间也保持显著差异。
- 3级急性毒性2例(1.2%)、3级晚期毒性3例(1.8%),无4-5级不良事件。
核心结论
- 质子治疗被证明有效且毒性特征可接受,据作者所知这是纳入接受质子治疗的颅内脑膜瘤患者的最大系列之一。
研究设计与样本
- 单中心回顾性分析,纳入2014至2021年间连续接受根治性质子治疗的颅内脑膜瘤患者,共167例。
- 良性/影像诊断与不典型/间变性颅内脑膜瘤的中位质子治疗处方剂量分别为55.8 Gy(相对生物效应,RBE)与66 GyRBE。
主要发现
- 中位随访41个月(范围6-99),12例(7%)出现肿瘤局部复发,中位复发时间39个月。
- 5年局部无复发生存率全队列为88%,良性/影像诊断组98% vs 不典型/间变性组47%(p<0.001)。
- 5年总生存率与5年远处无复发生存率在良性/影像诊断组与不典型/间变性组之间也保持显著差异。
- 年龄≤56岁患者结局显著更好,较低处方剂量与颅底位置与更好的无放射性坏死生存率相关。
- 3级急性毒性2例(1.2%),3级晚期毒性3例(1.8%),无4-5级不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the outcomes of a large series of intracranial meningiomas (IMs) submitted to proton therapy (PT) with curative intent. METHODS: We conducted a retrospective analysis on all consecutive IM patients treated between 2014 and 2021. The median PT prescription dose was 55.8 Gy relative biological effectiveness (RBE) and 66 GyRBE for benign/radiologically diagnosed and atypical/anaplastic IMs, respectively. Local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), overall survival (OS), and radionecrosis-free survival (RNFS) were evaluated with the Kaplan-Meier method. Univariable analysis was performed to identify potential prognostic factors for clinical outcomes. Toxicity was reported according to the latest Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS: Overall, 167 patients were included. With a median follow-up of 41 months (range, 6-99), twelve patients (7%) developed tumor local recurrence after a median time of 39 months. The 5-year LRFS was 88% for the entire cohort, with a significant difference between benign/radiologically diagnosed and atypical/anaplastic IMs (98% vs. 47%, p < 0.001); this significant difference was maintained also for the 5-year OS and the 5-year DRFS rates. Patients aged ≤ 56 years reported significantly better outcomes, whereas lower prescription doses and skull base location were associated with better RNFS rates. Two patients experienced G3 acute toxicities (1.2%), and three patients G3 late toxicities (1.8%). There were no G4-G5 adverse events. CONCLUSION: PT proved to be effective with an acceptable toxicity profile. To the best of our knowledge this is one of the largest series including IM patients submitted to PT.
引用
- Iannalfi A, Riva G, Lillo S, et al. Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes. J Neurooncol. 2024. PMID: 38918319. doi:10.1007/s11060-024-04751-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。